What were MiniMed (NASDAQ:MMED)’s Q4 2026 net sales?

MiniMed reported fourth-quarter net sales of $837 million, up 15.6% year-over-year. On an organic basis, sales grew 8.7%, reflecting strong demand for its continuous glucose monitoring (CGM) technologies.

How did MiniMed (NASDAQ:MMED) perform for the full fiscal year 2026?

Full-year net sales reached $3.102 billion, a 14.2% increase over fiscal 2025. Organic revenue growth was 8%, driven by international expansion and higher CGM adoption among insulin pump users.

What drove MiniMed’s (NASDAQ:MMED) record 2026 performance?

Growth was supported by rising CGM attachment rates, international market expansion, and an increasing share of insulin pump users bundling devices with integrated CGM sensors for recurring consumables revenue.

What is MiniMed’s (NASDAQ:MMED) fiscal 2027 revenue outlook?

The company projects approximately 10% organic revenue growth for fiscal 2027, including a 1% to 1.5% operational tailwind from an extra calendar week.

Image for illustrative purposes only. Not a real photo.

MiniMed hits record $3.1B in fiscal 2026 sales, issues strong outlook

Q: How is MiniMed (NASDAQ:MMED) managing operational efficiency?

Management expects to sustain operational efficiency and capture manufacturing scale, forecasting an adjusted EBITDA margin of roughly 16% for fiscal 2027.

Written by Liezl GambePublished Jun. 3 2026Last Updated Jun. 3 2026

MiniMed (NASDAQ:MMED) reported a 15.6% increase in fourth-quarter net sales to $837 million, closing out a record-setting fiscal year 2026 driven by strong international adoption and rising attachment rates for its continuous glucose monitoring (CGM) technologies.

On an organic basis, fourth-quarter sales grew 8.7% compared to the same period last year, demonstrating resilient underlying demand for automated insulin delivery systems.

For the full fiscal year 2026, the company's total net sales climbed 14.2% to a record $3.102 billion, up from the prior year's totals.

Full-year organic revenue grew 8%.

The record performance was heavily anchored by accelerating commercial footprint expansion in international markets and an increasing proportion of insulin pump users opting to bundle their devices with integrated CGM sensors, which provides a predictable stream of recurring consumables revenue.

Looking ahead to fiscal year 2027, MiniMed issued an optimistic financial forecast, projecting organic revenue growth of approximately 10%.

This forward-looking top-line target includes a 1% to 1.5% operational tailwind attributed to an extra calendar week in the upcoming fiscal period.

Furthermore, management expects to sustain operational efficiency and capture manufacturing scale, forecasting an adjusted EBITDA margin of approximately 16% for the full year.